Several randomized controlled trials have proven the efficacy of the implantable cardioverter-defibrillator (ICD) at preventing sudden cardiac death in patients with advanced systolic heart failure.
1-3 These trials excluded patients who were in the acute phase of a myocardial infarction (MI), had recent coronary revascularization, had New York Heart Association (NYHA) class IV symptoms, or had newly diagnosed heart failure. In other clinical trials, survival benefit from ICD therapy could not be demonstrated in patients recovering from an acute MI and patients who received an ICD at the time of coronary artery bypass graft (CABG) surgery.
4-6